Results 61 to 70 of about 2,052,688 (283)

Uncoupling Type I Interferon Benefits From Inflammatory Toxicity: Transformer‐Prioritized Precision Agonists for Potent and Safer Cancer Immunotherapy

Advanced Science, EarlyView.
A Transformer‐based AI framework, DLINP, screens millions of compounds to identify Co68, a cobalt‐pincer organometallic complex that biases TLR4‐MD2 signaling toward antitumor interferon activation while suppressing inflammatory toxicity through an early TLR4‐SYK‐STAT1 axis.
Xuefei Guo, Yang Zhao, Xianle Rong, Xingyu Chen, Xiao Wang, Tianyi Liu, Yunfei Xie, Yushu Zou, Pingsen Zhao, Qiang Liu, Fuping You   +10 more
wiley   +1 more source

T cell receptor-engineered T cells for leukemia immunotherapy

Cancer Cell International, 2019
At present, refractory and relapse are major issues for leukemia therapy and a major cause of allogeneic hematopoietic stem cell transplant failure. Over the last decade, many studies have demonstrated that adoptive cancer antigen-specific T cell therapy
Yikai Zhang, Yangqiu Li
doaj   +1 more source

Additional file 2: of Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy

, 2016
Preparation of chimeric antigen receptor-modified (CAR) T cells targeting CD19 (CART19).
Chengfei Pu (3443966), He Huang (50693), Aiyun Jin (3443960), Yongxian Hu (327027), Lei Xiao (166081), Bin Liang (228729), Yi Luo (143206), Jian Yu (141239), Qu Cui (198237), Jie Sun (74648), Jimin Shi (576453), Zhao Wu (3443963)   +11 more
core   +1 more source

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia [PDF]

, 2015
Current therapies for acute myeloid leukemia are associated with high failure and relapse rates. Adoptive immunotherapies, which have shown promise in the treatment of hematologic malignancies, have the potential to target acute myeloid leukemia through ...
Joshua F. Heiber, Ingo Schubert, Georg Fey, Carol O’Hear, Terrence L. Geiger   +4 more
core   +1 more source

convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting [PDF]

, 2020
We have developed a chimeric antigen receptor (CAR) platform that functions as a modular system to address limitations of traditional CAR therapies. An inert form of the human NKG2D extracellular domain (iNKG2D) was engineered as the ectodomain of the ...
Roybal, Kole T, Williams, Steven R, Steiger, Daniel, Lok, Stephen, Landgraf, Kyle E, Gebhart, Dana, Martin, David W, Kim, Kaman Chan   +7 more
core   +1 more source

SynNotch Receptors for Visualizing Immunoreceptor Force Transmission and Downstream Signaling In Vivo

Advanced Science, EarlyView.
A mechanically activated SynNotch reporter platform enables detection of force transmission through receptors as they mediate immune cell interactions. Targeting CD40 on B cells and TCR on T cells records force‐induced reporter activation across 2D coculture, 3D organoid, and implanted in mice, which also reveal force‐amplification of immune receptor ...
Menglan Li, Jintian Lyu, Kaitao Li, Ameya Dravid, Deepali Balasubramani, Amir H. K. Ashkezari, Hyun‐Kyu Choi, Gabriel A. Kwong, Ankur Singh, Cheng Zhu   +9 more
wiley   +1 more source

Chimeric antigen receptor-natural killer

Journal of Bone Marrow Transplantation and Cellular Therapy
Chimeric antigen receptor (CAR) technology has transformed adoptive cell therapy, particularly through the success of CAR-T cells in hematologic malignancies.
Larissa Cardoso Zanetti, Raquel de Melo Alves Paiva, Lucila Nassif Kerbauy   +2 more
doaj   +1 more source

An Engineered HR1‐Stem Helix‐HR2 Trimeric Platform for Developing Broad‐Spectrum Coronavirus Vaccines

Advanced Science, EarlyView.
Sun et al. report a self‐assembling trimeric subunit vaccine platform termed RHS, which integrates the JN.1 receptor‐binding domain (RBD) with the heptad repeat 1 (HR1), stem helix (SH), and heptad repeat 2 (HR2) regions. The SARS‐CoV‐2 RHS vaccine elicits variant‐reactive RBD‐specific antibodies and cross‐reactive SH‐specific antibodies against ...
Xikui Sun, Junhao Fan, Xiaolu Xie, Yuting Shi, Xiaoqing Liu, Tiefeng Xu, Sidi Yang, Keda Shi, Chengshu Xie, Shixiong Li, Siwen Chen, Ruoxi Cai, Ping He, Yuzhen Ye, Tao Chen, Xiancai Ma, Chunmei Li, Jingyou Yu, Deyin Guo   +18 more
wiley   +1 more source

Chimeric Antigen Receptor—Macrophages in Pancreatic Cancer: Promise, Pitfalls, and the Path Ahead

Frontiers in Bioscience-Elite
Chimeric antigen receptor–engineered macrophages (CAR-Ms) are emerging as a transformative frontier in immunotherapy and represent a promising strategy for pancreatic cancer.
Palloma Porto Almeida, Leandro Martins de Freitas   +1 more
doaj   +1 more source

Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy

Beni-Suef University Journal of Basic and Applied Sciences, 2022
Background Findings of new targeted treatments with adequate safety evaluations are essential for better cancer cures and mortality rates. Immunotherapy holds promise for patients with relapsed disease, with the ability to elicit long-term remissions ...
Amina Hussain
doaj   +1 more source